MargaretLMacmillanMDMSc, FRCPC

Pediatric Hematology & Oncology • Minneapolis, MN

Pediatric Hematologic Oncology

Professor of Pediatrics, Director, Blood and Marrow Transplantation & Cellular Therapy Program University of Minnesota Medical School

Join to view full profile

Dr. Macmillan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Macmillan's full profile

Already have an account?

Office
MMC 484
420 Delaware St SE
Minneapolis, MN 55455
Phone+1 612-626-2961

Education & Training

University of Toronto Faculty of MedicineClass of 1991

Certifications & Licensure

MN State Medical License 1999 - 2025

Clinical Trials

Stem Cell Transplantation for Fanconi Anemia Start of enrollment: 2004 Mar 01
Terminated
Phase 1, Phase 2
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) Start of enrollment: 1999 Nov 18
Completed
Phase 1, Phase 2
Stem Cell Transplantation for Hematological Malignancies Start of enrollment: 2000 Jun 07
Terminated
Phase 2, Phase 3
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia Start of enrollment: 2002 Mar 26
Completed
Phase 2
TBI Dose De-escalation for Fanconi Anemia Start of enrollment: 2006 May 18
Completed
Phase 2, Phase 3
HSCT for High Risk Inherited Inborn Errors Start of enrollment: 2006 Sep 01
Completed
Phase 2
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Start of enrollment: 2007 Jul 23
Completed
Phase 1
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation Start of enrollment: 1999 Jun 01
Terminated
Phase 1, Phase 2
Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia Start of enrollment: 2000 Feb 17
Completed
Phase 1, Phase 2
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2008 Jun 01
Terminated
Phase 1
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation Start of enrollment: 2013 Nov 08
Completed
Phase 1
Busulfan and Cyclophosphamide Followed By ALLO BMT Start of enrollment: 2013 Jan 01
Terminated
Not Applicable
Pediatric cGVHD Symptom Scale Start of enrollment: 2019 Oct 02
Recruiting
Roles: Contact
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies Start of enrollment: 2023 May 11
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
Longitudinal clinical manifestations of Fanconi anemia: A systematized review.
Alex Hoover, Lucie M Turcotte, Rachel Phelan, Crystal Barbus, Arpana Rayannavar
Blood Reviews. 2024-11-01
Incidence of bacterial blood stream infections in patients with acute GVHD.
Whitney Wallis, Alison M Gulbis, Tao Wang, Catherine J Lee, Akshay Sharma
Bone Marrow Transplantation. 2024-10-18
2 citations
Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis.
Nosha Farhadfar, Nahid Rashid, Karen Chen, Jakob DeVos, Tao Wang
Blood Advances. 2024-09-24

Journal Articles

Amphiregulin in Intestinal Acute Graft-Versus-Host Disease: A Possible Diagnostic and Prognostic Aid
Brittney Schultz, Bruce R Blazar, Daniel J Weisdorf, Shernan G Holtan, Alexander Khoruts, Armin Rashidi, Margaret L MacMillan, Khalid Amin, Byron P Vaughn, Nature
Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value in Isolation or with Other Graft-Versus-Host Disease Symptoms as Currently Diagnos...
Margaret MacMillan, Sophie Paczesny, Ran Reshef, Daniel Weisdorf, Haematologica
Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment Kinetics
Erhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica

Abstracts/Posters

Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation
Margaret L. MacMillan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)
Margaret L. MacMillan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Adult and Pediatric BMT
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Validation of Minnesota Acute Gvhd Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All Gvhd Is Created Equal
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018